Freenome, Inc.

PCSC, a blank-check company targeting the life sciences and healthcare diagnostics sector, filed a 424B3 prospectus with the Securities and Exchange Commission on August 27, 2026, in connection with its proposed business combination with Freenome, Inc., a San Francisco-based biotechnology company developing blood-based, multi-omics cancer screening tests powered by artificial intelligence. Freenome has concentrated its clinical pipeline on early-detection assays for colorectal and other cancers, positioning the combined entity at the intersection of diagnostics and computational biology. The 424B3 filing, bearing accession number 0001140361-26-034715, represents a key regulatory step in the de-SPAC process for PCSC. Visit SpacDesk and sign up for full data, filings, and deal-status analytics on PCSC and every active SPAC transaction.